L

Lytix Biopharma AS
OSE:LYTIX

Watchlist Manager
Lytix Biopharma AS
OSE:LYTIX
Watchlist
Price: 9.26 NOK -1.91% Market Closed
Market Cap: 632.1m NOK

Wall Street
Price Targets

LYTIX Price Targets Summary
Lytix Biopharma AS

Wall Street analysts forecast LYTIX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LYTIX is 13.26 NOK with a low forecast of 13.13 NOK and a high forecast of 13.65 NOK.

Lowest
Price Target
13.13 NOK
42% Upside
Average
Price Target
13.26 NOK
43% Upside
Highest
Price Target
13.65 NOK
47% Upside
Lytix Biopharma AS Competitors:
Price Targets
NVAX
Novavax Inc
63% Upside
FHTX
Foghorn Therapeutics Inc.
80% Upside
CANTA
Cantargia AB
34% Upside
ALXO
ALX Oncology Holdings Inc
130% Upside
AMGN
Amgen Inc
4% Upside
PTCT
PTC Therapeutics Inc
9% Upside
096530
Seegene Inc
77% Upside
002675
Yantai Dongcheng Biochemicals Co Ltd
21% Upside

Revenue
Forecast

Revenue Estimate
Lytix Biopharma AS

For the last 6 years the compound annual growth rate for Lytix Biopharma AS's revenue is 79%. The projected CAGR for the next 2 years is 46%.

79%
Past Growth
46%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Lytix Biopharma AS

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Lytix Biopharma AS

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is LYTIX's stock price target?
Price Target
13.26 NOK

According to Wall Street analysts, the average 1-year price target for LYTIX is 13.26 NOK with a low forecast of 13.13 NOK and a high forecast of 13.65 NOK.

What is Lytix Biopharma AS's Revenue forecast?
Projected CAGR
46%

For the last 6 years the compound annual growth rate for Lytix Biopharma AS's revenue is 79%. The projected CAGR for the next 2 years is 46%.

Back to Top